Savran Technologies

Savran Technologies is a private, pre-revenue diagnostics company pioneering a novel, non-invasive approach to predicting preeclampsia. Its technology platform isolates ultra-rare cells from urine to detect upstream biomarkers as early as 10 weeks of gestation, far earlier than current methods. The company's lead program received FDA Breakthrough Device Designation in January 2026, validating its potential to address a major unmet need in maternal-fetal health. SavranTech is positioned to tap into a large global market by enabling timely, prophylactic intervention to prevent adverse outcomes.

Patented platform for the capture and detection of ultra-rare cells from biofluids (e.g., urine), enabling non-invasive analysis of upstream disease biomarkers.

Current standard of care (blood pressure and proteinuria monitoring) is indirect and late-stage, representing an inferior substitute. SavranTech's primary competition comes from other early-stage companies and academic efforts developing multi-analyte blood tests or other urine-based biomarkers for preeclampsia prediction, but a clinically validated, FDA-designated urine test for first-trimester use appears to be a first-in-class opportunity.